vemurafenib

vemurafenib

美 　英

• 網絡威羅菲尼；威羅菲尼片；維羅非尼

例句

Roche's vemurafenib attacks advanced melanoma by blocking the mutated form of a gene, B-RAF.

羅氏公司的vemurafenib通過阻斷一種突變的基因B-RAF攻擊晚期黑色素瘤。

One study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.

周日美國臨床腫瘤學會召開的學術會議中一項針對試驗用藥vemurafenib的研究引起關注。

This month Roche submitted an application to the Food and Drug Administration (FDA) for a new melanoma drug, vemurafenib.

本月，羅氏（Roche）向食品及藥物管理局（FDA）提交了一種黑素瘤藥品vemurafenib。

In a large, phase 3 study involving 675 people worldwide, patients on vemurafenib did much better than those on chemotherapy.

在一項全球有675名病患參與的三組對照研究中，vemurafenib的療效遠高于化療。

While patients taking vemurafenib do very well, Schuchter said the drug stops working after about nine or 10 months.

病患服用vemurafenib后效果良好，舒特說服藥9-10個月藥物才失效。

Vemurafenib blocks the mutated gene, which kills the cancer cell and shrinks tumors.

他強調vemurafenib阻斷變異的基因，從而殺死腫瘤細胞令腫瘤萎縮。

Those taking vemurafenib had a 63% reduced risk of death compared to those on chemo.

與化療組相比，vemurafenib組的病患死亡風險下降了63%。